CAR-T Cells: Current Status, Challenges, and Future Prospects

Abstract

As chimeric antigen receptor (CAR)-T cell therapy has expanded rapidly to meet the growing global cancer burden; many challenges have emerged as a critical factor influencing its efficacy. However, due to the complicated mechanisms of CAR-T cells, human interference alone was insufficient to optimize the outcomes. In parallel, artificial intelligence (AI) has begun to intersect with CAR-T cells, offering novel computational interferences that can refine therapeutic mechanisms. The literature is still lacking a comprehensive investigation that merges CAR-T cell mechanistic biology and limitations with the advancing abilities of AI to meet these barriers. This review provides an overview of the mechanistic foundations of CAR-T cell. It also investigates the various challenges facing the current CAR-T therapies including toxicity, resistance, and accessibility issues. On this basis, we examined the way AI-based innovations are being utilized to optimize the CAR-T engineering and clinical management. Finally, we examined clinical studies and case studies incorporating AI elements, emphasizing both therapeutic mechanisms and outcomes of the study. By integrating mechanistic biology with computational innovation, this review provides a unified unique perspective that can guide the development of safer and more effective CAR-T therapies.

Keywords

chimeric antigen receptor / trogocytosis / mechanisms / challenges / algorithm / and machine learning

References

[1] R. Nair and J. Westin. CAR T-Cells. In: A Naing, J Hajjar, (eds). “Immunotherapy” 3. (Cham: Springer International Publishing, 2020): 215–233.

[2] S. Du, J. Yan, Y. Xue, Y. Zhong, and Y. Dong, “Adoptive Cell Therapy for Cancer Treatment,” Exploration (Beijing, China) 3 (2023): 20210058.

[3] S. F. Anne-Elise, Z. Roxana, A. Simona, G. Oana, B. Florina, and P. Virgil, “Car T Cells Therapy versus Tils Therapy: The Future of Cancer Immunotherapy,” Editorial Board 96 (1982): 4.

[4] Y. Kuwana, Y. Asakura, N. Utsunomiya, et al., “Expression of Chimeric Receptor Composed of Immunoglobulin-derived V Resions and T-cell Receptor-derived C Regions,” Biochemical and Biophysical Research Communications 149 (1987): 960–968.

[5] G. Gross, T. Waks, and Z. Eshhar, “Expression of Immunoglobulin-T-cell Receptor Chimeric Molecules as Functional Receptors With Antibody-type Specificity,” Proceedings of the National Academy of Sciences of the United States of America 86 (1989): 10024–10028.

[6] T. Asmamaw Dejenie, G. Tiruneh, M. Medhin, et al., “Current Updates on Generations, Approvals, and Clinical Trials of CAR T-cell Therapy,” Human Vaccines & Immunotherapeutics 18 (2022): 2114254.

[7] M. Sadelain, R. Brentjens, and I. Rivière, “The Basic Principles of Chimeric Antigen Receptor Design,” Cancer Discovery 3 (2013): 388–398.

[8] Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, “Specific Activation and Targeting of Cytotoxic Lymphocytes Through Chimeric Single Chains Consisting of Antibody-binding Domains and the Gamma or Zeta Subunits of the Immunoglobulin and T-cell Receptors,” Proceedings of the National Academy of Sciences of the United States of America 90 (1993): 720–724.

[9] J. Maher, R. J. Brentjens, G. Gunset, I. Rivière, and M. Sadelain, “Human T-lymphocyte Cytotoxicity and Proliferation Directed by a Single Chimeric TCRζ/CD28 Receptor,” Nature Biotechnology 20 (2002): 70–75.

[10] C. Carpenito, M. C. Milone, R. Hassan, et al., “Control of Large, Established Tumor Xenografts With Genetically Retargeted human T Cells Containing CD28 and CD137 Domains,” Proceedings of the National Academy of Sciences of the United States of America 106 (2009): 3360–3365.

[11] M. Chmielewski, C. Kopecky, A. A. Hombach, and H. Abken, “IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression,” Cancer Research 71 (2011): 5697–5706.

[12] Y. Kagoya, S. Tanaka, T. Guo, et al., “A Novel Chimeric Antigen Receptor Containing a JAK–STAT Signaling Domain Mediates Superior Antitumor Effects,” Nature Medicine 24 (2018): 352–359.

[13] A. N. Miliotou and L. C. Papadopoulou, “CAR T-cell Therapy: A New Era in Cancer Immunotherapy,” Current Pharmaceutical Biotechnology 19 (2018): 5–18.

[14] K. Miyake and H. Karasuyama, “The Role of Trogocytosis in the Modulation of Immune Cell Functions,” Cells 10 (2021): 1255.

[15] C. Liu, T. Qi, J. J. Milner, Y. Lu, and Y. Cao, “Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response,” Frontiers in Immunology 12 (2021): 748768.

[16] S. L. Maude, T. W. Laetsch, J. Buechner, et al., “Tisagenlecleucel in Children and Young Adults With B-cell Lymphoblastic Leukemia,” New England Journal of Medicine 378 (2018): 439–448.

[17] S. S. Neelapu, F. L. Locke, N. L. Bartlett, et al., “Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma,” New England Journal of Medicine 377 (2017): 2531–2544.

[18] F. Luciani, A. Safavi, P. Guruprasad, L. Chen, and M. Ruella, “Advancing CAR T-cell Therapies With Artificial Intelligence: Opportunities and Challenges,” Blood Cancer Discovery 6 (2025): 159–162.

[19] D. Hudson, R. A. Fernandes, M. Basham, G. Ogg, and H. Koohy, “Can We Predict T Cell Specificity With Digital Biology and Machine Learning?,” Nature Reviews Immunology 23 (2023): 511–521.

[20] A. Mösch, S. Raffegerst, M. Weis, D. J. Schendel, and D. Frishman, “Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors,” Frontiers in Genetics 10 (2019): 1141.

[21] F. Ramezani, A. R. Panahi Meymandi, B. Akbari, et al., “Outsmarting Trogocytosis to Boost CAR NK/T Cell Therapy,” Molecular Cancer 22 (2023): 183.

[22] K. Newick, S. O'Brien, E. Moon, and S. M. Albelda, “CAR T Cell Therapy for Solid Tumors,” Annual Review of Medicine 68 (2017): 139–152.

[23] S. S. Neelapu, S. Tummala, P. Kebriaei, et al., “Chimeric Antigen Receptor T-cell Therapy—assessment and Management of Toxicities,” Nature Reviews Clinical Oncology 15 (2018): 47–62.

[24] E. Schoutrop, S. Renken, I. Micallef Nilsson, et al., “Trogocytosis and Fratricide Killing Impede MSLN-directed CAR T Cell Functionality,” Oncoimmunology 11 (2022): 2093426.

[25] R. G. Majzner and C. L. Mackall, “Clinical Lessons Learned From the First Leg of the CAR T Cell Journey,” Nature Medicine 25 (2019): 1341–1355.

[26] C. Zhang, Q. Zhuang, J. Liu, and X. Liu, “Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering,” ACS Synthetic Biology 11 (2022): 1–15.

[27] P. H. Mehta, G. S. Trollope, P. Leung, et al., “Choice of Activation Protocol Impacts the Yield and Quality of CAR T Cell Product, Particularly With Older Individuals,” Clinical & Translational Immunology 13 (2024): e70016.

[28] E. Zhang and H. Xu, “A New Insight in Chimeric Antigen Receptor-engineered T Cells for Cancer Immunotherapy,” Journal of Hematology & Oncology 10 (2017): 1–11.

[29] M. H. Abbasi, A. Riaz, M. B. Khawar, A. Farooq, A. Majid, and N. Sheikh, “CAR-T-Cell Therapy: Present Progress and Future Strategies,” Biomedical Research and Therapy 9 (2022): 4920–4929.

[30] S. Cullen and S. Martin, “Mechanisms of Granule-dependent Killing,” Cell Death & Differentiation 15 (2008): 251–262.

[31] M.-K. Song, B.-B. Park, and J.-E. Uhm, “Resistance Mechanisms to CAR T-cell Therapy and Overcoming Strategy in B-cell Hematologic Malignancies,” International Journal of Molecular Sciences 20 (2019): 5010.

[32] G. de Saint Basile, G. Ménasché, and A. Fischer, “Molecular Mechanisms of Biogenesis and Exocytosis of Cytotoxic Granules,” Nature Reviews Immunology 10 (2010): 568–579.

[33] L. Martínez-Lostao, A. Anel, and J. Pardo, “How Do Cytotoxic Lymphocytes Kill Cancer Cells?,” Clinical Cancer Research 21 (2015): 5047–5056.

[34] S. Nagata and M. Tanaka, “Programmed Cell Death and the Immune System,” Nature Reviews Immunology 17 (2017): 333–340.

[35] T. Tatsumi, J. Huang, W. E. Gooding, et al., “Intratumoral Delivery of Dendritic Cells Engineered to Secrete both Interleukin (IL)-12 and IL-18 Effectively Treats Local and Distant Disease in Association With Broadly Reactive Tc1-type Immunity,” Cancer Research 63 (2003): 6378–6386.

[36] G. Ghilardi, E. Chong, J. Svoboda, et al., “Bendamustine Is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients With Refractory or Relapsed Large B-cell Lymphomas,” Annals of Oncology 33 (2022): 916–928.

[37] A. Aucher, E. Magdeleine, E. Joly, and D. Hudrisier, “Capture of Plasma Membrane Fragments From Target Cells by Trogocytosis Requires Signaling in T Cells but Not in B Cells,” Blood, The Journal of the American Society of Hematology 111 (2008): 5621–5628.

[38] N. Martinez-Martin and B. Alarcon, “Physiological and Therapeutic Relevance of T Cell Receptor-mediated Antigen Trogocytosis,” Biomedical Journal 47, no. 5 (2024): 100630.

[39] J. Reed and S. A. Wetzel, “Trogocytosis-mediated Intracellular Signaling in CD4+ T Cells Drives TH2-associated Effector Cytokine Production and Differentiation,” The Journal of Immunology 202 (2019): 2873–2887.

[40] K. Miyake, N. Shiozawa, T. Nagao, S. Yoshikawa, Y. Yamanishi, and H. Karasuyama, “Trogocytosis of Peptide–MHC Class II Complexes From Dendritic Cells Confers Antigen-presenting Ability on Basophils,” Proceedings of the National Academy of Sciences of the United States of America 114 (2017): 1111–1116.

[41] J. C. Charpentier and P. D. King, “Mechanisms and Functions of Endocytosis in T Cells,” Cell Communication and Signaling 19 (2021): 92.

[42] M. Hamieh, A. Dobrin, A. Cabriolu, et al., “CAR T Cell Trogocytosis and Cooperative Killing Regulate Tumour Antigen Escape,” Nature 568 (2019): 112–116.

[43] B. Chung, T. B. Stuge, J. P. Murad, et al., “Antigen-specific Inhibition of High-avidity T Cell Target Lysis by Low-avidity T Cells via Trogocytosis,” Cell Reports 8 (2014): 871–882.

[44] R. Brown, H. Suen, J. Favaloro, et al., “Trogocytosis Generates Acquired Regulatory T Cells Adding Further Complexity to the Dysfunctional Immune Response in Multiple Myeloma,” Oncoimmunology 1 (2012): 1658–1660.

[45] F. L. Locke and M. L. Davila, “Regulatory Challenges and Considerations for the Clinical Application of CAR-T Cell Anti-cancer Therapy,” Expert Opinion on Biological Therapy 17 (2017): 659–661.

[46] R. Joy, K. Phair, R. O'Hara, and D. Brady, “Recent Advances and Current Challenges in CAR-T Cell Therapy,” Biotechnology Letters 46 (2024): 115–126.

[47] A. M. Cushman-Vokoun, K. V. Voelkerding, M. K. Fung, et al., “A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?,” Archives of Pathology & Laboratory Medicine 145 (2021): 704–716.

[48] A. Daei Sorkhabi, L. Mohamed Khosroshahi, A. Sarkesh, et al., “The Current Landscape of CAR T-cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies,” Frontiers in Immunology 14 (2023): 1113882.

[49] R. C. Sterner and R. M. Sterner, “CAR-T Cell Therapy: Current Limitations and Potential Strategies,” Blood Cancer Journal 11 (2021): 69.

[50] J. G. Borrega, P. Gödel, M. A. Rüger, et al., “In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy,” Hemasphere 3 (2019): e191.

[51] M. D. Jain, M. Smith, and N. Shah, “How I Treat Refractory CRS and ICANS After CAR T-cell Therapy,” The Journal of the American Society of Hematology 141 (2023): 2430–2442.

[52] N. T. Funderburg, C. L. Shive, Z. Chen, et al., “Interleukin 6 Blockade With tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated human Immunodeficiency Virus Infection,” Clinical Infectious Diseases 77 (2023): 272–279.

[53] J. N. Brudno and J. N. J. Kochenderfer, “Current Understanding and Management of CAR T Cell-associated Toxicities,” Nature Reviews Clinical oncology 21, no. 7 (2024): 501–521.

[54] A. Afrough, P. R. Abraham, L. Turer, et al., “Toxicity of CAR T-Cell Therapy for Multiple Myeloma,” Acta Haematologica 21, no. 7 (2024): 501–521.

[55] N. Ahmed, O. Oluwole, Z. Mahmoudjafari, N. Suleman, and J. P. McGuirk, “Managing Infection Complications in the Setting of Chimeric Antigen Receptor T Cell (CAR-T) Therapy,” Clinical Hematology International 6 (2024): 31.

[56] C. L. Flugel, R. G. Majzner, G. Krenciute, et al., “Overcoming on-target, off-tumour Toxicity of CAR T Cell Therapy for Solid Tumours,” Nature Reviews Clinical Oncology 20 (2023): 49–62.

[57] A. Mishra, R. Maiti, P. Mohan, and P. Gupta, “Antigen Loss Following CAR-T Cell Therapy: Mechanisms, Implications, and Potential Solutions,” European Journal of Haematology 112 (2024): 211–222.

[58] A. Naghizadeh, W. Tsao-c, H. J. Cho, et al., “In Vitro Machine Learning-based CAR T Immunological Synapse Quality Measurements Correlate With Patient Clinical Outcomes,” Plos Computational Biology 18 (2022): e1009883.

[59] L. Liu, C. Ma, Z. Zhang, et al., “Computational Model of CAR T-cell Immunotherapy Dissects and Predicts Leukemia Patient Responses at Remission, Resistance, and Relapse,” Journal for ImmunoTherapy of Cancer 10 (2022): e005360.

[60] W. Szlasa, A. Sztuder, A. Kaczmar-Dybko, A. Maciejczyk, and J. J. B. Dybko, “Pharmacotherapy,” Efficient Combination of Radiotherapy and CAR-T–A Systematic Review 174 (2024): 116532.

[61] G. Guzman, M. R. Reed, K. Bielamowicz, B. Koss, and A. Rodriguez, “CAR-T Therapies in Solid Tumors: Opportunities and Challenges,” Current Oncology Reports 25 (2023): 479–489.

[62] K. Zhang, H. Chen, F. Li, S. Huang, F. Chen, and Y. Li, “Bright Future or Blind Alley? CAR-T Cell Therapy for Solid Tumors,” Frontiers in Immunology 14 (2023): 1045024.

[63] R. Borgert, “Improving Outcomes and Mitigating Costs Associated With CAR T-cell Therapy,” American Journal of Managed Care 27, no. 13 Suppl (2021): S253–S261.

[64] S. Depil, P. Duchateau, S. Grupp, G. Mufti, and L. Poirot, “Off-the-shelf'allogeneic CAR T Cells: Development and Challenges,” Nature Reviews Drug Discovery 19 (2020): 185–199.

[65] Y. Li, R. Basar, G. Wang, et al., “KIR-based Inhibitory CARs Overcome CAR-NK Cell Trogocytosis-mediated Fratricide and Tumor Escape,” Nature Medicine 28 (2022): 2133–2144.

[66] L. Gil and M. Grajek, “Artificial Intelligence and Chimeric Antigen Receptor T-cell Therapy,” Acta Haematologica Polonica 53 (2022): 176–179.

[67] U. Nukala, M. Rodriguez Messan, O. N. Yogurtcu, X. Wang, and H. Yang, “A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy,” The Aaps Journal [Electronic Resource] 23 (2021): 1–20.

[68] N. McGranahan, R. Rosenthal, C. T. Hiley, et al., “Allele-specific HLA Loss and Immune Escape in Lung Cancer Evolution,” Cell 171 (2017): 1259–1271. e11.

[69] J. Wang, X. Wang, P. Dang, et al., “A Data-driven and AI-empowered Systems Biology Model of MHC Class I Antigen Presentation Pathway,” Cancer Research 83 (2023): 3000–3000.

[70] S. Ferdous, I. F. Shihab, R. Chowdhury, and N. F. Reuel, “Reinforcement Learning-guided Control Strategies for CAR T-cell Activation and Expansion,” Biotechnology and Bioengineering (2023).

[71] T. Xie, A. Huang, H. Yan, X. Ju, L. Xiang, and J. Yuan, “Artificial Intelligence: Illuminating the Depths of the Tumor Microenvironment,” Journal of Translational Medicine 22 (2024): 799.

[72] B. de Jesus Rodrigues, L. R. Carvalho Barros, and R. C. Almeida, Three-compartment model of CAR T-cell immunotherapy. bioRxiv (2019):779793.

[73] P. Sahoo, X. Yang, D. Abler, et al., “Mathematical Deconvolution of CAR T-cell Proliferation and Exhaustion From Real-time Killing Assay Data,” Journal of the Royal Society Interface 17 (2020): 20190734.

[74] C. Liu, V. S. Ayyar, X. Zheng, et al., “Model-based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans,” Clinical Pharmacology & Therapeutics 109 (2021): 716–727.

[75] D. K. Zhang, K. Adu-Berchie, S. Iyer, et al., “Enhancing CAR-T cell functionality in a patient-specific manner,” Nature Communications 14 (2023): 506.

[76] I. Verkouter, A. Vegelien, I. Beekers, et al., “Mathematical Optimization of Personalized CAR-T Cell Products,” 5th European CAR T-cell Meeting. Virtual: European Hematology Association (EHA) & EBMT.

[77] A. Bogatu, M. Wysocka, O. Wysocki, et al., “Meta-analysis Informed Machine Learning: Supporting Cytokine Storm Detection During CAR-T Cell Therapy,” Journal of Biomedical Informatics 142 (2023): 104367.

[78] D. Gibson, C. Leonforte, and A. Madrigal, “Strategies for Dealing With Donor Variability,” Cell and Gene Therapy Insights 4, no. 9 (2018): 901–909.

[79] S. J. Reyes, Y. Durocher, P. L. Pham, and O. Henry, “Modern Sensor Tools and Techniques for Monitoring, Controlling, and Improving Cell Culture Processes,” Processes 10 (2022): 189.

[80] S. Hort, L. Herbst, N. Bäckel, et al., “Toward Rapid, Widely Available Autologous CAR-T Cell Therapy–artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital,” Frontiers in Medicine 9 (2022): 913287.

[81] D.-N. Vo, N. Leventoux, M. Campos-Mora, S. Gimenez, P. Corbeau, and M. Villalba, “NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living With HIV-1,” Vaccines 10 (2022): 688.

[82] D.-N. Vo, M. Constantinides, N. Allende-Vega, C. Alexia, G. Cartron, and M. Villalba, “Dissecting the NK Cell Population in Hematological Cancers Confirms the Presence of Tumor Cells and Their Impact on NK Population Function,” Vaccines 8 (2020): 727.

[83] M. Campos-Mora, W. Jacot, G. Garcin, et al., “NK Cells in Peripheral Blood Carry Trogocytosed Tumor Antigens From Solid Cancer Cells,” Frontiers in Immunology 14 (2023): 1199594.

[84] R. Velmurugan, “Using Advanced Microscopy Techniques for the Study of Macrophage-Cancer Cell Interactions in the Presence of Therapeutic Antibodies,” (2017).

[85] E. Ferrero, I. Dunham, and P. Sanseau, “In Silico Prediction of Novel Therapeutic Targets Using Gene–disease Association Data,” Journal of Translational Medicine 15 (2017): 182.

[86] J. Gan, J. H. Cho, R. Lee, et al., “Methods of Machine Learning-Based Chimeric Antigen Receptor Immunological Synapse Quality Quantification,” The Immune Synapse: Methods and Protocols: Springer 2654 (2023): 493–502.

[87] M. Lee, Y.-H. Lee, J. Song, et al., “Deep-learning-based Three-dimensional Label-free Tracking and Analysis of Immunological Synapses of CAR-T Cells,” Elife 9 (2020): e49023.

[88] D. C. Kirouac, C. Zmurchok, A. Deyati, J. Sicherman, C. Bond, and P. W. Zandstra, “Deconvolution of Clinical Variance in CAR-T Cell Pharmacology and Response,” Nature Biotechnology 41 (2023): 1606–1617.

[89] C. H. June and M. Sadelain, “Chimeric Antigen Receptor Therapy,” New England Journal of Medicine 379 (2018): 64–73.

[90] K. E. Blise, S. Sivagnanam, C. B. Betts, et al., “Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer,” Cancer Immunology Research 12 (2024): 544–558.

[91] J. Song, F. Huang, L. Chen, et al., “Identification of Methylation Signatures Associated With CAR T Cell in B-cell Acute Lymphoblastic Leukemia and Non-hodgkin's Lymphoma,” Frontiers in Oncology 12 (2022): 976262.

[92] C. C. Zebley, C. Brown, T. Mi, et al., “CD19-CAR T Cells Undergo Exhaustion DNA Methylation Programming in Patients With Acute Lymphoblastic Leukemia,” Cell Reports 37, no. 9 (2021): 110079.

[93] R. Zhang, X. Han, Z. Lei, et al., “RCMNet: A Deep Learning Model Assists CAR-T Therapy for Leukemia,” Computers in Biology and Medicine 150 (2022): 106084.

[94] K. G. Daniels, S. Wang, M. S. Simic, et al., “Decoding CAR T Cell Phenotype Using Combinatorial Signaling Motif Libraries and Machine Learning,” Science 378 (2022): 1194–1200.

[95] F. Huber, M. Arnaud, B. J. Stevenson, et al., “A Comprehensive Proteogenomic Pipeline for Neoantigen Discovery to Advance Personalized Cancer Immunotherapy,” Nature Biotechnology 43, no. 8 (2024): 1360–1372.

[96] M. Müller, F. Huber, M. Arnaud, et al., “Machine Learning Methods and Harmonized Datasets Improve Immunogenic Neoantigen Prediction,” Immunity 56 (2023): 2650–2663. e6.

[97] A. Bulashevska, Z. Nacsa, F. Lang, et al., “Artificial Intelligence and Neoantigens: Paving the Path for Precision Cancer Immunotherapy,” Frontiers in Immunology 15 (2024): 1394003.

[98] F. Füchsl, J. Untch, V. Kavaka, et al., “High-resolution Profile of Neoantigen-specific TCR Activation Links Moderate Stimulation to Increased Resilience of Engineered TCR-T Cells,” Nature Communications 15 (2024): 10520.

[99] P. Hayden, C. Roddie, P. Bader, et al., “Management of Adults and Children Receiving CAR T-cell Therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA),” Annals of Oncology 33 (2022): 259–275.

[100] C. Zuo, J. Xia, and L. Chen, “Dissecting Tumor Microenvironment From Spatially Resolved Transcriptomics Data by Heterogeneous Graph Learning,” Nature Communications 15 (2024): 5057.

[101] I. Duran, J. Pombo, B. Sun, et al., “Detection of Senescence Using Machine Learning Algorithms Based on Nuclear Features,” Nature Communications 15 (2024): 1041.

[102] V. Smer-Barreto, A. Quintanilla, R. J. Elliott, et al., “Discovery of Senolytics Using Machine Learning,” Nature Communications 14 (2023): 3445.

[103] C. Wu, J. Cui, X. Xu, and D. Song, “The Influence of Virtual Environment on Thermal Perception: Physical Reaction and Subjective Thermal Perception on Outdoor Scenarios in Virtual Reality,” International Journal of Biometeorology 67 (2023): 1291–1301.

[104] X. Shen, B. Wang, Z. He, H. Zhou, and Y. Zhou, “Biology-based AI Predicts T-cell Receptor Antigen Binding Specificity,” Academic Journal of Science and Technology 10 (2024): 23–27.

[105] D. T. Teachey, S. F. Lacey, P. A. Shaw, et al., “Identification of Predictive Biomarkers for Cytokine Release Syndrome After Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia,” Cancer Discovery 6 (2016): 664–679.

[106] M. Su, L. Chen, L. Xie, et al., “Identification of Early Predictive Biomarkers for Severe Cytokine Release Syndrome in Pediatric Patients With Chimeric Antigen Receptor T-cell Therapy,” Frontiers in Immunology 15 (2024): 1450173.

[107] J. Paludo, J. T. Shreve, E. Contreras Guzman, et al., “Machine Learning-based Prediction of Cytokine Release Syndrome post CAR-T Cell Therapy,” American Society of Clinical Oncology (2025).

[108] Z. Wei, J. Xu, C. Zhao, et al., “Prediction of Severe CRS and Determination of Biomarkers in B Cell-acute Lymphoblastic Leukemia Treated With CAR-T Cells,” Frontiers in Immunology 14 (2023): 1273507.

[109] J. J. Huang, E. C. Liang, A. Albittar, et al., “Early Prediction of Severe ICANS After Standard-of-care CD19 CAR T-cell Therapy Using Gradient-boosted Classification Trees,” American Society of Clinical Oncology (2024).

[110] G. Grevera, J. Udupa, D. Odhner, et al., “CAVASS: A Computer-assisted Visualization and Analysis Software System,” Journal of Digital Imaging 20 (2007): 101–118.

[111] Y. Tong, J. K. Udupa, E. Chong, et al., “Prediction of Lymphoma Response to CAR T Cells by Deep Learning-based Image Analysis,” PLoS ONE 18 (2023): e0282573.

[112] K. A. Al-Utaibi, A. Nutini, A. Sohail, R. Arif, S. Tunc, and S. M. Sait, “Forecasting the Action of CAR-T Cells Against SARS-corona Virus-II Infection With Branching Process,” Modeling Earth Systems and Environment 8 (2022): 3413–3421.

[113] J. J. Calis, M. Maybeno, J. A. Greenbaum, et al., “Properties of MHC Class I Presented Peptides That Enhance Immunogenicity,” PLoS Computational Biology 9 (2013): e1003266.

[114] T. Lu, Z. Zhang, J. Zhu, et al., “Deep Learning-based Prediction of the T Cell Receptor–antigen Binding Specificity,” Nature Machine Intelligence 3 (2021): 864–875.

[115] F. Huemer, M. Leisch, R. Geisberger, et al., “Combination Strategies for Immune-checkpoint Blockade and Response Prediction by Artificial Intelligence,” International Journal of Molecular Sciences 21 (2020): 2856.

[116] R. Dannenfelser, G. M. Allen, B. VanderSluis, et al., “Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies,” Cell Systems 11 (2020): 215–228. e5.

[117] N. Bäckel, S. Hort, T. Kis, et al., “Elaborating the Potential of Artificial Intelligence in Automated CAR-T Cell Manufacturing,” Frontiers in Molecular Medicine 3 (2023): 1250508.

[118] J. Yang, Y. Chen, Y. Jing, M. R. Green, and L. Han, “Advancing CAR T Cell Therapy Through the Use of Multidimensional Omics Data,” Nature Reviews Clinical oncology 20 (2023): 211–228.

[119] S. S. Raj, T. Fei, S. Fried, et al., “An Inflammatory Biomarker Signature of Response to CAR-T Cell Therapy in Non-Hodgkin Lymphoma,” Nature Medicine 31, no. 4 (2025): 1183–1194.

[120] G. Li, J. Peachey, P. Chew, and P. O'Neill, “A Digital Twin on CAR-T Cytokine Release Syndrome (CRS) Patients With Standard of Care Measured by CRS Distribution by Grade,” Applied Clinical Trials 26 (2023).

[121] M. Mehrian, T. Lambrechts, M. Marechal, F. P. Luyten, I. Papantoniou, and L. Geris, “Predicting in Vitro human Mesenchymal Stromal Cell Expansion Based on Individual Donor Characteristics Using Machine Learning,” Cytotherapy 22 (2020): 82–90.

[122] C. A. Duran-Villalobos, S. Goldrick, and B. Lennox, “Multivariate Statistical Process Control of an Industrial-scale Fed-batch Simulator,” Computers & Chemical Engineering 132 (2020): 106620.

[123] S. Goldrick, V. Sandner, M. Cheeks, et al., “Multivariate Data Analysis Methodology to Solve Data Challenges Related to Scale-up Model Validation and Missing Data on a Micro-bioreactor System,” Biotechnology Journal 15 (2020): 1800684.

[124] S. Vernardis, C. Goudar, and M. Klapa, “Metabolomics and Network Biology for Sensitive Monitoring of How Growth Environment Changes Affect the Physiology of Industrial-scale Perfusion Cultures,” IFAC Proceedings Volumes 46 (2013): 227–232.

[125] S. Li, A. Todor, and R. Luo, “Blood Transcriptomics and Metabolomics for Personalized Medicine,” Computational and Structural Biotechnology Journal 14 (2016): 1–7.

[126] S. Szentpéteri, K. B. Kis, P. Egri, et al., “Reinforcement Learning Based Resource Management for CAR T-Cell Therapies,” ScienceDirect 125 (2024): 154–159.

[127] P. Egri, B. C. Csáji, K. B. Kis, et al., “Bio-inspired Control of Automated Stem Cell Production,” Procedia CIRP 88 (2020): 600–605.

[128] A. M. Mc Laughlin, P. A. Milligan, C. Yee, M. Bergstrand, and S. Pharmacology, “Model-informed Drug Development of Autologous CAR-T Cell Therapy: Strategies to Optimize CAR-T Cell Exposure Leveraging Cell Kinetic/Dynamic Modeling,” Pharmacometrics & Systems Pharmacology 12 (2023): 1577–1590.

[129] T. Kis, S. Hort, P. Györgyi, E. Szögi, and R. H. Schmitt, “A Production Scheduling and Control System for CAR T Cell Manufacturing,” Procedia CIRP 125 (2024): 36–41.

[130] R. P. Taylor and M. A. Lindorfer, “Measurement of Trogocytosis: Quantitative Analyses Validated With Rigorous Controls,” Current Protocols 3 (2023): e897.

[131] S. Ge, S. Sun, H. Xu, Q. Cheng, and Z. Ren, “Deep Learning in Single-cell and Spatial Transcriptomics Data Analysis: Advances and Challenges From a Data Science Perspective,” Briefings in Bioinformatics 26 (2025): bbaf136.

[132] A. Talkington, C. Dantoin, and R. Durrett, “Ordinary Differential Equation Models for Adoptive Immunotherapy,” Bulletin of Mathematical Biology 80 (2018): 1059–1083.

[133] D. Hardiansyah and C. M. Ng, “Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-cell Therapy,” Clinical and Translational Science 12 (2019): 343–349.

[134] A. M. Stein, S. A. Grupp, J. E. Levine, et al., “Tisagenlecleucel Model-based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells,” CPT: Pharmacometrics & Systems Pharmacology 8 (2019): 285–295.

[135] J. A. Rohrs, D. Zheng, N. A. Graham, P. Wang, and S. D. Finley, “Computational Model of Chimeric Antigen Receptors Explains Site-specific Phosphorylation Kinetics,” Biophysical Journal 115 (2018): 1116–1129.

[136] J. A. Rohrs, E. L. Siegler, P. Wang, and S. D. Finley, “ERK Activation in CAR T Cells Is Amplified by CD28-mediated Increase in CD3ζ Phosphorylation,” Iscience 23, no. 4 (2020): 101023.

[137] S. Hanson Mathematical Modelling of Immuno-oncology and Related Immunology (Duke University, 2019).

[138] S. Hanson, D. R. Grimes, J. P. Taylor-King, et al. Toxicity Management in CAR T cell therapy for B-ALL: Mathematical modelling as a new avenue for improvement. bioRxiv (2016):049908.

[139] A. P. Singh, X. Zheng, X. Lin-Schmidt, et al., “Development of a Quantitative Relationship Between CAR-affinity, Antigen Abundance, Tumor Cell Depletion and CAR-T Cell Expansion Using a Multiscale Systems PK-PD Model,” In: Conference Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model, 2020, p. 1688616. Taylor & Francis.

[140] G. J. Kimmel, F. L. Locke, and P. M. Altrock, “Response to CAR T Cell Therapy Can be Explained by Ecological Cell Dynamics and Stochastic Extinction Events,” (2019): 717074.

[141] O. C. Finney, H. Brakke, S. Rawlings-Rhea, et al., “CD19 CAR T Cell Product and Disease Attributes Predict Leukemia Remission Durability,” The Journal of Clinical Investigation 129 (2019): 2123–2132.

[142] R. Mostolizadeh, Z. Afsharnezhad, and A. Marciniak-Czochra, “Mathematical Model of Chimeric Anti-gene Receptor (CAR) T Cell Therapy With Presence of Cytokine,” Numerical Algebra, Control and Optimization 8 (2018): 63–80.

[143] J. K. Lin, B. J. Lerman, J. I. Barnes, et al., “Cost Effectiveness of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Pediatric B-cell Acute Lymphoblastic Leukemia,” Journal of Clinical Oncology 36 (2018): 3192–3202.

[144] J. Furzer, S. Gupta, P. C. Nathan, et al., “Cost-effectiveness of tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada,” Jama Oncology 6 (2020): 393–401.

[145] R. R. Sarkar, N. J. Gloude, D. Schiff, and J. D. Murphy, “Cost-effectiveness of Chimeric Antigen Receptor T-cell Therapy in Pediatric Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia,” JNCI: Journal of the National Cancer Institute 111 (2019): 719–726.

[146] J. A. Roth, S. D. Sullivan, V. W. Lin, et al., “Cost-effectiveness of axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Large B-cell Lymphoma in the United States,” Journal of Medical Economics 21 (2018): 1238–1245.

[147] G. J. Kimmel, F. L. Locke, and P. M. Altrock, “The Roles of T Cell Competition and Stochastic Extinction Events in Chimeric Antigen Receptor T Cell Therapy,” Proceedings Biological Sciences 288 (2021): 20210229.

[148] V. Belleudi, F. Trotta, F. Fortinguerra, et al., “Real World Data to Identify Target Population for New CAR-T Therapies,” Pharmacoepidemiology and Drug Safety 30 (2021): 78–85.

[149] M. Wang, K. V. Komanduri, D. Datta, et al., “An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population With DLBCL,” Blood Advances (2025). bloodadvances. 2025016375.

[150] S. Capponi and K. G. Daniels, “Harnessing the Power of Artificial Intelligence to Advance Cell Therapy,” Immunological Reviews 320 (2023): 147–165.

[151] A. Naghizadeh, W.-C. Tsao, J. Hyun Cho, et al., “In Vitro Machine Learning-based CAR T Immunological Synapse Quality Measurements Correlate With Patient Clinical Outcomes,” PLoS Computational Biology 18 (2022): e1009883.

[152] L. Judijanto, “AI-Driven Innovations in Translational Research: Accelerating Bench-to-Bedside Pipelines through Predictive Modelling and Digital Biomarkers,” European Journal of Applied Science, Engineering and Technology 3 (2025): 138–148.

[153] Y. Chen, R. Ren, L. Yan, et al., “From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies,” Advanced Science 12 (2025): e05822.

[154] D. Andreu-Sanz, L. Gregor, E. Carlini, D. Scarcella, C. Marr, and S. Kobold, “Predictive Value of Preclinical Models for CAR-T Cell Therapy Clinical Trials: A Systematic Review and Meta-analysis,” Journal for ImmunoTherapy of Cancer 13 (2025): e011698.

[155] F. Xiong, M. Janko, M. Walker, et al., “Analysis of Cytokine Release Assay Data Using Machine Learning Approaches,” International Immunopharmacology 22 (2014): 465–479.

[156] S. S. Aghamiri and R. Amin, “The Potential Use of Digital Twin Technology for Advancing CAR-T Cell Therapy,” Current Issues in Molecular Biology 47 (2025): 321.

[157] K. H. Johansen, D. S. Wolff, B. Scapolo, et al., “De Novo-designed pMHC Binders Facilitate T Cell–mediated Cytotoxicity Toward Cancer Cells,” Science 389 (2025): 380–385.

[158] Z. Wei, C. Zhao, M. Zhang, et al., “PrCRS: A Prediction Model of Severe CRS in CAR-T Therapy Based on Transfer Learning,” BMC Bioinformatics [Electronic Resource] 25 (2024): 197.

[159] S. Raj, T. Fei, M. Corona, et al., “Multi-Modal Tumor, Host, and Product Features Synergistically Identify CAR-T Treatment Failure Risk in Large B-Cell Lymphoma,” Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy 31 (2025): S35–S36.

[160] Y. Ni, L. Zhu, and S. Li. Bio AI Agent: A Multi-Agent Artificial Intelligence System for Autonomous CAR-T Cell Therapy Development with Integrated Target Discovery, Toxicity Prediction, and Rational Molecular Design. arXiv preprint arXiv:251108649 (2025).

[161] O. L. Reddy, D. F. Stroncek, and S. R. Panch, “Improving CAR T Cell Therapy by Optimizing Critical Quality Attributes,” In: Conference Improving CAR T cell therapy by optimizing critical quality attributes, 2020, pp. 33–38. Elsevier.

[162] S. J. Keating, T. Gu, M. P. Jun, and A. McBride, “Health Care Resource Utilization and Total Costs of Care Among Patients With Diffuse Large B Cell Lymphoma Treated With Chimeric Antigen Receptor T Cell Therapy in the United States,” Transplantation and Cellular Therapy 28 (2022): 404. e1–04. e6.

[163] D. P. Turicek, V. M. Giordani, J. Moraly, N. Taylor, and N. N. Shah, “CAR T-cell Detection Scoping Review: An Essential Biomarker in Critical Need of Standardization,” Journal for Immunotherapy of Cancer 11 (2023): e006596.

[164] D. Cirillo, I. Núñez-Carpintero, and A. Valencia, “Artificial Intelligence in Cancer Research: Learning at Different Levels of Data Granularity,” Molecular Oncology 15 (2021): 817–829.

[165] C. S. Santos and M. Amorim-Lopes, “Externally Validated and Clinically Useful Machine Learning Algorithms to Support Patient-related Decision-making in Oncology: A Scoping Review,” BMC Medical Research Methodology 25 (2025): 45.

[166] J. P. Gygi, S. H. Kleinstein, and L. Guan, “Predictive Overfitting in Immunological Applications: Pitfalls and Solutions,” Human Vaccines & Immunotherapeutics 19 (2023): 2251830.

[167] R. Tsopra, X. Fernandez, C. Luchinat, et al., “A Framework for Validating AI in Precision Medicine: Considerations From the European ITFoC Consortium,” BMC Medical Informatics and Decision Making 21 (2021): 274.

[168] S. Macheka, P. Y. Ng, O. Ginsburg, A. Hope, R. Sullivan, and A. Aggarwal, “Prospective Evaluation of Artificial Intelligence (AI) Applications for Use in Cancer Pathways Following Diagnosis: A Systematic Review,” BMJ Oncology 3 (2024): e000255.

[169] A. M. Ng, K. M. MacKinnon, A. A. Cook, et al., “Mechanistic in Silico Explorations of the Immunogenic and Synergistic Effects of Radiotherapy and Immunotherapy: A Critical Review,” Physical and Engineering Sciences in Medicine 47 (2024): 1291–1306.

[170] E.-M. Froicu, I. Creangă-Murariu, V.-A. Afrăsânie, et al., “Artificial Intelligence and Decision-Making in Oncology: A Review of Ethical, Legal, and Informed Consent Challenges,” Current Oncology Reports 27, no. 8 (2025): 1002–1012.

[171] K. Murphy, E. Di Ruggiero, R. Upshur, et al., “Artificial Intelligence for Good Health: A Scoping Review of the Ethics Literature,” BMC Medical Ethics 22 (2021): 14.

[172] K. Moulaei, S. Akhlaghpour, and F. Fatehi, “Patient Consent for the Secondary Use of Health Data in Artificial Intelligence (AI) Models: A Scoping Review,” International Journal of Medical Informatics 198 (2025): 105872.

[173] A. E. Andrea, A. Chiron, S. Bessoles, and S. Hacein-Bey-Abina, “Engineering next-generation CAR-T Cells for Better Toxicity Management,” International Journal of Molecular Sciences 21 (2020): 8620.

[174] A. Boretti, “The Transformative Potential of AI-driven CRISPR-Cas9 Genome Editing to Enhance CAR T-cell Therapy,” Computers in Biology and Medicine 182 (2024): 109137.

[175] M. Shahzadi, H. Rafique, A. Waheed, et al., “Artificial Intelligence for Chimeric Antigen Receptor-based Therapies: A Comprehensive Review of Current Applications and Future Perspectives,” Therapeutic Advances in Vaccines and Immunotherapy 12 (2024): 25151355241305856.

[176] Z. Peelay, V. M. Patil, and A. Bhattacharjee, “Optimizing CAR T-cell Therapy for Glioblastoma: AI, Dose Selection, and Future Directions,” Discover Medicine 2 (2025): 1–16.

[177] S. Srivastava, A. Tyagi, V. A. Pawar, et al., “Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies,” ImmunoTargets and Therapy 13 (2024): 413–433.

[178] D. Anurogo, D. Luthfiana, N. Anripa, et al., “The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management,” Advanced Pharmaceutical Bulletin 14 (2024): 314.

[179] G. Dagar, A. Gupta, T. Masoodi, et al., “Harnessing the Potential of CAR-T Cell Therapy: Progress, Challenges, and Future Directions in Hematological and Solid Tumor Treatments,” Journal of Translational Medicine 21 (2023): 449.

[180] W.-Y. Zhang, X.-L. Zheng, P. S. Coghi, J.-H. Chen, B.-J. Dong, and X.-X. Fan, “Revolutionizing Adjuvant Development: Harnessing AI for next-generation Cancer Vaccines,” Frontiers in Immunology 15 (2024): 1438030.

[181] A. Murias-Closas, C. Prats, G. Calvo, D. López-Codina, and E. Olesti, “Computational Modelling of CAR T-cell Therapy: From Cellular Kinetics to Patient-level Predictions,” Ebiomedicine 113 (2025): 105597.

[182] E. Claes, T. Heck, K. Coddens, M. Sonnaert, J. Schrooten, and J. Verwaeren, “Bayesian Cell Therapy Process Optimization,” Biotechnology and Bioengineering 121 (2024): 1569–1582.

[183] G. Shouse, A. Kaempf, M. J. Gordon, et al., “A Validated Composite Comorbidity Index Predicts Outcomes of CAR T-cell Therapy in Patients With Diffuse Large B-cell Lymphoma,” Blood Advances 7 (2023): 3516–3529.

[184] B. Derraz, G. Breda, C. Kaempf, et al., “New Regulatory Thinking Is Needed for AI-based Personalised Drug and Cell Therapies in Precision Oncology,” NPJ Precision Oncology 8 (2024): 23.

[185] D. C. Kirouac, C. Zmurchok, A. Deyati, J. Sicherman, C. Bond, and P. W. Zandstra, “Deconvolution of Clinical Variance in CAR-T Cell Pharmacology and Response,” Nature Biotechnology 41 (2023): 1606–1617.

[186] K. G. Daniels, S. Wang, M. S. Simic, et al., “Decoding CAR T Cell Phenotype Using Combinatorial Signaling Motif Libraries and Machine Learning,” Science 378 (2022): 1194–1200.

[187] J. An, C.-P. Zhang, H.-Y. Qiu, et al., “Enhancement of the Viability of T Cells Electroporated With DNA via Osmotic Dampening of the DNA-sensing cGAS–STING Pathway,” Nature Biomedical Engineering 8 (2024): 149–164.

[188] W. Zhang, L. Yang, and X. Fan, “CAR-T Therapy-Based Innovations in the Enhancement of Contemporary Anti-tumor Therapies,” Frontiers in Immunology 16 (2025): 1622433.

[189] A. Ali and J. F. DiPersio, “ReCARving the Future: Bridging CAR T-cell Therapy Gaps With Synthetic Biology, Engineering, and Economic Insights,” Frontiers in Immunology 15 (2024): 1432799.

[190] J. Yang, Y. Chen, Y. Jing, M. R. Green, and L. Han, “Advancing CAR T Cell Therapy Through the Use of Multidimensional Omics Data,” Nature Reviews Clinical Oncology 20 (2023): 211–228.

[191] A. Gottschlich, M. Thomas, R. Grünmeier, et al., “Single-cell Transcriptomic Atlas-guided Development of CAR-T Cells for the Treatment of Acute Myeloid Leukemia,” Nature Biotechnology 41 (2023): 1618–1632.

[192] J. BAENA, J. S. Victoria, A. Toro-Pedroza, et al., “Smart CAR-T Nanosymbionts: Archetypes and Proto-models,” Frontiers in Immunology 16 (2025): 1635159.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.